ATE460406T1 - Bicyclische verbindung, deren herstellung und verwendung - Google Patents

Bicyclische verbindung, deren herstellung und verwendung

Info

Publication number
ATE460406T1
ATE460406T1 AT02762751T AT02762751T ATE460406T1 AT E460406 T1 ATE460406 T1 AT E460406T1 AT 02762751 T AT02762751 T AT 02762751T AT 02762751 T AT02762751 T AT 02762751T AT E460406 T1 ATE460406 T1 AT E460406T1
Authority
AT
Austria
Prior art keywords
production
bicyclic compound
bicyclic
compound
Prior art date
Application number
AT02762751T
Other languages
German (de)
English (en)
Inventor
Mitsuru Shiraishi
Masanori Baba
Katsuji Aikawa
Naoyuki Kanzaki
Masaki Seto
Yuji Iizawa
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Application granted granted Critical
Publication of ATE460406T1 publication Critical patent/ATE460406T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
AT02762751T 2001-08-08 2002-08-07 Bicyclische verbindung, deren herstellung und verwendung ATE460406T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12
PCT/JP2002/008043 WO2003014105A1 (en) 2001-08-08 2002-08-07 Bicyclic compound, production and use as hiv inhibitors

Publications (1)

Publication Number Publication Date
ATE460406T1 true ATE460406T1 (de) 2010-03-15

Family

ID=26620186

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02762751T ATE460406T1 (de) 2001-08-08 2002-08-07 Bicyclische verbindung, deren herstellung und verwendung
AT10150963T ATE539062T1 (de) 2001-08-08 2002-08-07 Bizyklishe verbindung, ihre herstellung und verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT10150963T ATE539062T1 (de) 2001-08-08 2002-08-07 Bizyklishe verbindung, ihre herstellung und verwendung

Country Status (13)

Country Link
US (7) US7371772B2 (enExample)
EP (3) EP1423376B1 (enExample)
JP (4) JP4316203B2 (enExample)
AR (1) AR034985A1 (enExample)
AT (2) ATE460406T1 (enExample)
AU (1) AU2002328092A1 (enExample)
CA (2) CA2607992A1 (enExample)
DE (1) DE60235632D1 (enExample)
DK (2) DK1423376T3 (enExample)
ES (2) ES2376855T3 (enExample)
PE (1) PE20030329A1 (enExample)
PT (2) PT1423376E (enExample)
WO (1) WO2003014105A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1423376T3 (da) 2001-08-08 2010-06-28 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
CN1649847A (zh) * 2002-03-12 2005-08-03 武田药品工业株式会社 制备旋光亚砜衍生物的方法
EP1593680A4 (en) * 2003-02-07 2008-05-07 Takeda Pharmaceutical PYRIDINE DERIVATIVES WITH CONDENSED RING, PROCESS FOR THEIR PREPARATION AND USE
WO2004069834A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 三環性化合物、その製造方法および用途
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
EP1728504B1 (en) * 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
EP1728505B1 (en) * 2004-03-24 2014-06-04 Takeda Pharmaceutical Company Limited Preparation with elevated content
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
EP1825866A4 (en) * 2004-12-03 2008-03-12 Takeda Pharmaceutical SOLID PREPARATION
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
BRPI0914457A2 (pt) * 2008-10-17 2015-10-27 Invasc Therapeutics Inc composto, composição farmacêutica, método para reduzir angiotensão convertendo atividade de enzima, método para tratar uma perturbação relacionada com o sistema de renina-angiotensina aldosterona, método para tratar derrame cerebral
CN102712629B (zh) 2009-11-27 2016-10-12 基酶有限公司 作为葡糖神经酰胺合酶的抑制剂的无定型和结晶形式的Genz112638半酒石酸盐
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JP6556825B2 (ja) * 2014-03-21 2019-08-07 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック
EP3148538A4 (en) * 2014-06-02 2018-01-17 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
AU2015314830B2 (en) 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CN107207538A (zh) * 2014-12-23 2017-09-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法
SG11201706028RA (en) 2015-02-10 2017-08-30 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
BR112018076449A2 (pt) * 2016-06-21 2019-04-09 Tobira Therapeutics, Inc. cenicriviroc purificado e intermediários purificados para fazer cenicriviroc
TW201823235A (zh) 2016-08-31 2018-07-01 美商托彼拉治療公司 西克里維羅（ｃｅｎｉｃｒｉｖｉｒｏｃ）甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法
EP3567028B1 (en) * 2016-12-09 2022-01-05 Medshine Discovery Inc. Biphenyl compound as ccr2/ccr5 receptor antagonist
AU2018223976B2 (en) 2017-02-24 2023-08-17 Genfit Pharmaceutical compositions for combination therapy
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
EP3988098B1 (en) * 2019-06-24 2024-07-24 Wuxi Life Fountain Biotech Co., Ltd. Heterocyclo alkyl compounds used as ccr2/ccr5 antagonists
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN115667247B (zh) * 2020-05-22 2024-04-12 南京明德新药研发有限公司 吡啶类衍生物及其应用
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用
WO2024240025A1 (zh) * 2023-05-22 2024-11-28 无锡瓴方生物医药科技有限公司 一种联合用药物组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CN1151744A (zh) 1994-07-04 1997-06-11 武田药品工业株式会社 膦酸化合物及其制备和应用
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
ATE270552T1 (de) 1997-10-20 2004-07-15 Dainippon Pharmaceutical Co Von tetrahydropyrrolo (1,2-a) pyrazin-4-spiro-3'- pyrrolidine stabilisierte zusammenstellung
CA2304959A1 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
CA2353635A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
ATE275392T1 (de) 1999-04-12 2004-09-15 Shionogi & Co Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
EP1211239A4 (en) 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd PROCESSES FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS
DK1423376T3 (da) 2001-08-08 2010-06-28 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
CN1649847A (zh) 2002-03-12 2005-08-03 武田药品工业株式会社 制备旋光亚砜衍生物的方法
EP1728505B1 (en) * 2004-03-24 2014-06-04 Takeda Pharmaceutical Company Limited Preparation with elevated content
EP1728504B1 (en) * 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
EP1825866A4 (en) 2004-12-03 2008-03-12 Takeda Pharmaceutical SOLID PREPARATION
US20080108586A1 (en) 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
BR112013012309A2 (pt) 2010-11-18 2016-08-23 Univ Yale composto, composição, métodos de tratamento e usos de um composto
US9434766B2 (en) 2011-06-27 2016-09-06 Universite Pierre Et Marie Curie (Paris 6) CCR2 antagonist peptides
KR20160013068A (ko) 2013-05-15 2016-02-03 토비라 쎄라퓨틱스, 인크. 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
JP6556825B2 (ja) 2014-03-21 2019-08-07 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック
CN107207538A (zh) 2014-12-23 2017-09-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法
SG11201706028RA (en) 2015-02-10 2017-08-30 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis

Also Published As

Publication number Publication date
US20120232028A1 (en) 2012-09-13
US8362058B2 (en) 2013-01-29
US20040259876A1 (en) 2004-12-23
EP2206702A1 (en) 2010-07-14
JP2009209154A (ja) 2009-09-17
EP1889839B1 (en) 2013-11-06
AU2002328092A1 (en) 2003-02-24
US7371772B2 (en) 2008-05-13
JP2007084578A (ja) 2007-04-05
ES2339340T3 (es) 2010-05-19
HK1142886A1 (en) 2010-12-17
US10045968B2 (en) 2018-08-14
JP2013136629A (ja) 2013-07-11
US20200297700A1 (en) 2020-09-24
ES2376855T3 (es) 2012-03-20
CA2459172A1 (en) 2003-02-20
EP2206702B1 (en) 2011-12-28
EP1889839A1 (en) 2008-02-20
PT2206702E (pt) 2012-02-03
ATE539062T1 (de) 2012-01-15
PE20030329A1 (es) 2003-05-12
JP5275148B2 (ja) 2013-08-28
DK2206702T3 (da) 2012-02-13
DK1423376T3 (da) 2010-06-28
WO2003014105A1 (en) 2003-02-20
JP4316203B2 (ja) 2009-08-19
WO2003014105A9 (en) 2003-11-20
US20160008326A1 (en) 2016-01-14
US8741943B2 (en) 2014-06-03
US8183273B2 (en) 2012-05-22
EP1423376B1 (en) 2010-03-10
JP4358851B2 (ja) 2009-11-04
US20080161287A1 (en) 2008-07-03
JP2003335776A (ja) 2003-11-28
US20090030032A1 (en) 2009-01-29
DE60235632D1 (de) 2010-04-22
CA2607992A1 (en) 2003-02-20
AR034985A1 (es) 2004-03-24
US20190038604A1 (en) 2019-02-07
PT1423376E (pt) 2010-04-12
EP1423376A1 (en) 2004-06-02
CA2459172C (en) 2011-07-05

Similar Documents

Publication Publication Date Title
ATE460406T1 (de) Bicyclische verbindung, deren herstellung und verwendung
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
DE60235547D1 (de) En daraus, deren herstellung und verwendung
ATE319684T1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE60225385D1 (de) Autentisches Document und dessen Herstellungsverfahren
ATE293644T1 (de) Polyolefin und die herstellung davon
DE60235531D1 (de) Verbundmaterialprodukt
DE60235142D1 (de) Kondensator und dessen Herstellungsverfahren
HUP0401293A3 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
DE60238358D1 (de) Naturkautschuk-masterbatch dessen Herstellungsverfahren, und Naturkautschukzusammensetzung
AU2003293757A1 (en) Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
ATE248186T1 (de) Antipicornavirale verbindungen, deren herstellung und verwendung
DE60200427D1 (de) Vernetzbare Fluorelastomerzusammensetzungen, ihre Herstellung und Verwendung
DE60015004D1 (de) Russ, seine Herstellung und Verwendungen
DE50208287D1 (de) Bicyclische n-arylamide
ATE326467T1 (de) Imidazo 1,2-aöpyridine
DE60216345D1 (de) Gummimischung und deren Verwendung
DE60200719D1 (de) Filmbildende Zusammensetzung, poröser Film und deren Herstellung
DE10251294B4 (de) Polyamidformmasse und deren Verwendung
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
ATE251170T1 (de) Titanverbindungen, deren herstellung und verwendung
DE60334632D1 (de) Mechanolumineszenzstoff und dessen herstellung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE50214244D1 (de) Klauenpolläufer und dessen herstellverfahren
EP1401791A4 (en) NON-PEPTIDE CYCLOPHILIN BINDING COMPOUNDS AND USES THEREOF

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1423376

Country of ref document: EP